These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
70. Low-dose botulinum toxin-a treatment of cervical dystonia - a double-blind, randomized pilot study. Laubis-Herrmann U; Fries K; Topka H Eur Neurol; 2002; 47(4):214-21. PubMed ID: 12037435 [TBL] [Abstract][Full Text] [Related]
71. Evaluation of therapeutic benefits of botulinum toxin for foot dystonia associated with Parkinson's disease. Ni P; Xu YY; Wang LN; Cao JQ; Luo WF; Zhang QL; Li X; Zhou XP; Liu J Toxicon; 2024 Feb; 238():107587. PubMed ID: 38142904 [TBL] [Abstract][Full Text] [Related]
72. Long-term follow-up of cervical dystonia patients treated with botulinum toxin A. Haussermann P; Marczoch S; Klinger C; Landgrebe M; Conrad B; Ceballos-Baumann A Mov Disord; 2004 Mar; 19(3):303-8. PubMed ID: 15022184 [TBL] [Abstract][Full Text] [Related]
73. [Diagnostic and therapeutic difficulties in laryngeal dystonia]. Niebudek-Bogusz E; Modzelewska-Radwan B; Pietruszewska W; Zielińska M; Gryczyński M Otolaryngol Pol; 2003; 57(5):739-45. PubMed ID: 14994622 [TBL] [Abstract][Full Text] [Related]
74. Botulinum A toxin treatment for blepharospasm and Meige syndrome: report of 100 patients. Poungvarin N; Devahastin V; Chaisevikul R; Prayoonwiwat N; Viriyavejakul A J Med Assoc Thai; 1997 Jan; 80(1):1-8. PubMed ID: 9078810 [TBL] [Abstract][Full Text] [Related]
75. Botulinum Toxin Therapy for Oromandibular Dystonia and Other Movement Disorders in the Stomatognathic System. Yoshida K Toxins (Basel); 2022 Apr; 14(4):. PubMed ID: 35448891 [TBL] [Abstract][Full Text] [Related]
76. Switch from abobotulinumtoxinA (Dysport®) to incobotulinumtoxinA (Xeomin®) botulinum toxin formulation: a review of 257 cases. Grosset DG; Tyrrell EG; Grosset KA J Rehabil Med; 2015 Feb; 47(2):183-6. PubMed ID: 25325305 [TBL] [Abstract][Full Text] [Related]
77. Botulinum toxin A and neuropathic pain: An update. Spagna A; Attal N Toxicon; 2023 Aug; 232():107208. PubMed ID: 37385479 [TBL] [Abstract][Full Text] [Related]
78. Long-term botulinum toxin treatment of benign essential blepharospasm, hemifacial spasm, and Meige syndrome. Czyz CN; Burns JA; Petrie TP; Watkins JR; Cahill KV; Foster JA Am J Ophthalmol; 2013 Jul; 156(1):173-177.e2. PubMed ID: 23541393 [TBL] [Abstract][Full Text] [Related]
79. Neurotoxins licensed as treatment for neck neuromuscular disorder. Am J Health Syst Pharm; 2001 Feb; 58(3):200, 202. PubMed ID: 11217174 [No Abstract] [Full Text] [Related]
80. Satisfaction with botulinum toxin treatment in post-stroke spasticity: results from two cross-sectional surveys (patients and physicians). Bensmail D; Hanschmann A; Wissel J J Med Econ; 2014 Sep; 17(9):618-25. PubMed ID: 24841450 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]